AndhraNews.net
Home » Business News » 2011 » March » March 29, 2011

Prescription Pharmaceutical Sales Will Shrink by $108 Billion Due to the Patent Cliff


March 29, 2011 - Rockville, MD

MarketResearch.com has announced the addition of Datamonitor's new report "Pharmaceutical Key Trends 2011 - Prescription Pharmaceutical Sales Overview" to their collection of Pharma market reports. For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=6206574

Prescription pharmaceutical sales in the world's major markets (US, France, Germany, Italy, Spain, the UK, Japan, Australia, Brazil, Russia, China and India) totaled $555bn in 2009, having grown by 6.3% during 2008-09, and at a compound annual growth rate (CAGR) of 5.6% between 2005 and 2009.

  • Examines the prescription pharmaceutical sales growth trends across the various different therapy areas
  • Assesses the leading prescription pharmaceutical brands across each of the 12 major pharma markets
  • Profiles the leading multinational and domestic pharma companies operating in each of the 12 major pharma markets
  • Analyzes the forecast sales according to lifecycle stage of drug, molecule type, source of drug, geographical market, therapy area and formulation

The US prescription pharmaceutical market generated half (50.3%) of the sales of the 12 markets analyzed, with $279bn in 2009, with sales having grown by 5.0% (CAGR, 2005-09) and 5.5% (2008-09). However, future sales growth will be shaped by three key events: the US economic downturn, healthcare reform and the patent cliff.

Pharma is set to lose approximately $108bn in sales due to the patent cliff during 2010-15, while the industry is also feeling the effect of the recent global economic downturn. However, Pharma is implementing a number of strategies to drive sales and profitability going forward: product innovation, diversification and cost-containment.

Growth in the emerging markets is driven by their rapidly growing economies and populations; expansion of healthcare systems and health insurance policies, increasing access to drugs; and the emergence of middle classes with disposable incomes, who are more likely to spend money on branded generics and branded pharmaceuticals.

For more information, visit http://www.marketresearch.com/product/display.asp?ProductID=6206574

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Veronica Franco
MarketResearch.com
Email Contact
240.747.3016

MarketWire

Comment on this story

Share